Selecting the optimal therapeutic regimen for patients at risk of anaphylaxis requires clinicians to balance clinical pharmacology with practical, real-world behaviors. While prompt administration of epinephrine remains the definitive standard of care, treatment adherence is frequently undermined by needle phobia, device bulk, prescription cost barriers, and confusion over adjunctive medications. To ensure patients and families are equipped to act quickly during an emergency, healthcare providers must navigate an expanding array of delivery devices, formulation kinetics, and coverage hurdles.

In Module 2 of Managing Anaphylaxis in the Real World, hosted by Sarah Williams, MAT, two leading allergy and immunology specialists—Manish Ramesh, MD, PhD, Chief of the Division of Allergy and Immunology at Montefiore Medical Center and Associate Professor at Albert Einstein College of Medicine, and Anna Nowak-Węgrzyn, MD, PhD, Professor of Pediatrics at NYU Grossman School of Medicine and Director of the Pediatric Allergy and Immunology Division at Hassenfeld Children's Hospital—examine the comparative pharmacology of oral antihistamines, clinical considerations between injectable and needle-free intranasal epinephrine, age- and weight-based dosing parameters, and pragmatic solutions to overcome cost and access challenges.

Second-Generation Antihistamines vs Diphenhydramine

For anaphylaxis, antihistamines are strictly secondary, adjunctive agents that do not halt the reaction; however, they are widely utilized for mild, localized cutaneous symptoms such as acute urticaria or oral pruritus. The speakers strongly advised against the historical reliance on first-generation agents like diphenhydramine in favor of second-generation oral antihistamines, specifically cetirizine.

“We prefer a second-generation because they’re non-sedating,” Dr. Nowak-Węgrzyn explained. “One of the side effects of a first-generation agent, like diphenhydramine, is sleepiness and drowsiness. Those are concerning behaviors, like the signs that we might mistake for a more serious reaction. It makes sense to use a drug that minimizes those side effects. In comparative studies, there was no advantage to diphenhydramine.”

Beyond avoiding diagnostic ambiguity caused by sedation, cetirizine offers distinct pharmacodynamic advantages: it maintains high cutaneous tissue concentrations, has an onset of action comparable to diphenhydramine, and provides a significantly longer duration of action.

Addressing formulation preferences, Dr. Nowak-Węgrzyn noted that while oral liquid solutions provide the fastest absorption, adherence often drops due to bottle size and portability issues. Rapidly dissolving oral disintegrating tablets or chewable formulations offer convenient, highly portable alternatives that prevent patients from leaving their medications behind. Dr. Ramesh stressed a fundamental rule of thumb: never let the burden of carrying bulky antihistamine bottles compromise epinephrine carriage.

“I would rather you prioritize the epinephrine over the bottle of antihistamine,” Dr. Ramesh emphasized. “Sometimes people don’t carry the whole package which has everything because it’s too big, and they end up with nothing, which would not be good.”

Autoinjectors vs Intranasal Administration

The emergence of non-invasive epinephrine delivery options represents a major shift designed to reduce hesitation and overcome needle-related barriers. When selecting between traditional autoinjectors and newly-approved intranasal formulations (or investigational sublingual films), shared decision making driven by patient comfort is paramount.

“To me, it’s a patient preference,” stated Dr. Nowak-Węgrzyn. “The bottom line is that I want them to use epinephrine, and I’ll do whatever I can to make it easier for them. We know that some people are really afraid of injecting. If they say ‘I prefer the spray,’ then yes, we’ll go with the spray.”

When evaluating candidates for intranasal epinephrine, clinicians must also evaluate specific anatomic and clinical boundaries. Dr. Ramesh noted that the key clinical question is often identifying when not to prescribe the nasal spray.

“For patients who had significant nasal surgery or have had an injury where it might be difficult for the drug to absorb, those are the cases where we say they may not be a good candidate for it,” Dr. Ramesh stated.

Importantly, common upper respiratory conditions do not impede drug delivery. Clinical pharmacokinetic data demonstrate that acute viral coryza or active allergic rhinitis do not diminish mucosal uptake; in fact, mucosal hypervascularity and inflammation may accelerate absorption.

Weight-Based Dosing Parameters in Infants and Young Children

Dosing accuracy in pediatric populations requires careful attention to developmental cutoffs. Intranasal epinephrine is approved down to two years of age (1 mg weight-based dosing threshold), leaving injectable epinephrine as the standard for infants.

For infants weighing under 15 kg, a dedicated 0.1-mg autoinjector is available, but access can be restricted by limited formulary coverage or manufacturer constraints. Both experts reinforced that insurance denial of a 0.1 mg device must never leave an infant unprotected.

“As we have done for years, maybe decades before that, 0.15 mg is the appropriate dose, and that’s what you should prescribe,” Dr. Ramesh affirmed.

Dr. Nowak-Węgrzyn agreed, underscoring that therapeutic safety margins far outweigh potential transient adrenergic effects: “We’ve been using 0.15 for ages before the 0.1 became available. There’s no absolute contraindication. If there’s serious, severe anaphylaxis, we just use epinephrine.”

Navigating Copays, Refills, and Expiration Realities

Financial constraints and high deductibles frequently result in prescription abandonment. Clinicians must actively assist patients in navigating pharmacy versus medical benefits, specialty mail-order programs, and manufacturer copay assistance cards.

To maintain coverage across multiple caregiver settings (eg, home, school, and parent bags), providers should routinely prescribe two twin packs. If a payer limits dispensing to a single twin pack per claim, writing recurring 30-day refills allows families to accumulate required sets across successive months. Clinicians should also remind families to verify expiration dates at the pharmacy counter prior to pick up, noting that while autoinjectors typically carry a 12-to-18–month shelf-life, intranasal formulations offer a longer 24-month stability window.

Finally, the experts addressed the common scenario of an expired device during an emergency. While manual syringe-and-needle aspiration from epinephrine ampules remains an unsafe, error-prone strategy during acute distress, an expired commercial device should never be discarded if no alternative exists. Provided the viewing window reveals clear, unprecipitated solution, an expired device retains substantial active drug potency and must be administered without delay in life-threatening anaphylaxis.

Key Takeaways

Second-generation antihistamines like cetirizine are preferred over diphenhydramine because they eliminate sedating side effects that confound clinical assessment while offering superior duration and cutaneous concentration.
Patients must prioritize carrying epinephrine above all else. If carrying bulky liquid antihistamines discourages adherence, rapidly dissolving tablets or chewables should be substituted.
Intranasal epinephrine bypasses needle apprehension and offers comparable bioavailability; it is suitable for patients with seasonal rhinitis or colds but is contraindicated in those with major nasal structural alterations or prior reconstructive surgery.
For infants under 15 kg, a 0.15-mg autoinjector should be promptly prescribed if insurance denies or restricts access to the 0.1-mg formulation.
Providers should prescribe two twin packs or stagger monthly refills to ensure adequate supplies for multiple caregivers, schools, and home environments.
During an acute emergency when no replacement is on hand, an expired autoinjector with clear, non-discolored liquid should be utilized rather than withholding life-saving epinephrine.

About the Speakers

Manish Ramesh, MD, PhD, is the Chief of the Division of Allergy and Immunology at Montefiore Medical Center and an Associate Professor of Allergy and Immunology at Albert Einstein College of Medicine. He specializes in the prevention and treatment of food allergies. Dr. Ramesh started the Food Allergy Center at Montefiore and developed an oral immunotherapy program for children and adults. He is passionate about improving care for patients with food allergies.

Anna Nowak-Wegrzyn, MD, PhD, is a Professor of Pediatrics at NYU Grossman School of Medicine and the Director of the Pediatric Allergy and Immunology Division at Hassenfeld Children's Hospital, NYU Langone Health. She specializes in the prevention and treatment of allergies in children. Dr. Nowak-Wegrzyn is passionate about helping patients navigate allergies and anaphylaxis from childhood into young adulthood. She also serves on the Board of Directors of the American Academy of Allergy, Asthma, and Immunology.

Managing Anaphylaxis in the Real World: Module 2—Considerations for Treatment Selection